Prospective Long-Term Follow-Up of Pulmonary Diffusion Capacity Reduction Caused by Dose-Dense Chemotherapy in Patients with Breast Cancer.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
12
2018
revised:
05
08
2019
accepted:
04
09
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
11
2019
Statut:
epublish
Résumé
Our previous study of pulmonary function in 34 patients with early breast cancer without preexisting lung disease showed that anthracycline- and taxane-based adjuvant dose-dense chemotherapy (DDC) caused a significant 16.4% mean reduction in carbon monoxide diffusing capacity (DLCO). The present study reports the pulmonary and oncological outcomes of these patients on long-term follow-up. The primary endpoint was DLCO measured by the pulmonary function test (PFT) performed at a median of 27 months after DDC (range, 8-97) in 25 patients without disease recurrence. DLCO values were recorded as a percentage of predicted values according to age, height, and hemoglobin level and analyzed relative to baseline pre-DDC DLCO values. The secondary endpoints were symptoms, additional therapies, and cancer outcomes during a median of 11 years' follow-up (range, 4.4-11.4). A longitudinal general linear model showed significant effects of time on DLCO and its trend ( The significant reduction in DLCO seen after DDC in patients with potentially curable breast cancer is evident years afterwards, especially in older patients. While most patients partly recover, some will have a lasting symptomatic DLCO impairment.
Sections du résumé
BACKGROUND
BACKGROUND
Our previous study of pulmonary function in 34 patients with early breast cancer without preexisting lung disease showed that anthracycline- and taxane-based adjuvant dose-dense chemotherapy (DDC) caused a significant 16.4% mean reduction in carbon monoxide diffusing capacity (DLCO). The present study reports the pulmonary and oncological outcomes of these patients on long-term follow-up.
PATIENTS AND METHODS
METHODS
The primary endpoint was DLCO measured by the pulmonary function test (PFT) performed at a median of 27 months after DDC (range, 8-97) in 25 patients without disease recurrence. DLCO values were recorded as a percentage of predicted values according to age, height, and hemoglobin level and analyzed relative to baseline pre-DDC DLCO values. The secondary endpoints were symptoms, additional therapies, and cancer outcomes during a median of 11 years' follow-up (range, 4.4-11.4).
RESULTS
RESULTS
A longitudinal general linear model showed significant effects of time on DLCO and its trend (
CONCLUSIONS
CONCLUSIONS
The significant reduction in DLCO seen after DDC in patients with potentially curable breast cancer is evident years afterwards, especially in older patients. While most patients partly recover, some will have a lasting symptomatic DLCO impairment.
Identifiants
pubmed: 31772578
doi: 10.1155/2019/2584859
pmc: PMC6854974
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2584859Informations de copyright
Copyright © 2019 Yosef Landman et al.
Déclaration de conflit d'intérêts
The authors have declared no conflicts of interest.
Références
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):701-7
pubmed: 21398052
Cancer Invest. 2016 Nov 25;34(10):536-545
pubmed: 27824512
Eur Respir J. 2017 Feb 8;49(2):
pubmed: 28179436
J Clin Oncol. 2003 Apr 15;21(8):1431-9
pubmed: 12668651
J Chemother. 2017 Apr;29(2):113-117
pubmed: 25978147
Cancer Treat Rev. 2014 Dec;40(10):1199-214
pubmed: 25458605
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):e565-70
pubmed: 22929860
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1381-8
pubmed: 16757130
Radiother Oncol. 2018 Jan;126(1):148-154
pubmed: 29246585
Ann Allergy Asthma Immunol. 2009 Mar;102(3):179-87; quiz 187-9, 222
pubmed: 19354063
Bone Marrow Transplant. 2001 May;27(10):1109-11
pubmed: 11438830
Eur Respir J. 2005 Oct;26(4):720-35
pubmed: 16204605
Qual Life Res. 2018 Aug;27(8):2077-2086
pubmed: 29740782
Breast Cancer (Dove Med Press). 2017 May 29;9:375-381
pubmed: 28615970
Chest. 2012 Jul;142(1):175-184
pubmed: 22194584
Am J Respir Crit Care Med. 2000 Jan;161(1):17-25
pubmed: 10619792
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Strahlenther Onkol. 2018 Jun;194(6):520-532
pubmed: 29450591
J Clin Oncol. 2018 Aug 1;36(22):2326-2347
pubmed: 29782209
World J Surg Oncol. 2014 Jul 22;12:230
pubmed: 25052797
Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):411-9
pubmed: 11380228
Physiol Rep. 2018 Jan;6(2):
pubmed: 29368799
Support Care Cancer. 2018 Oct;26(10):3649-3658
pubmed: 29730714
Chest. 2001 Nov;120(5):1695-701
pubmed: 11713155
Ann Oncol. 2009 Mar;20(3):437-40
pubmed: 19139179
Environ Toxicol Pharmacol. 2018 Mar;58:70-76
pubmed: 29306104
Br J Radiol. 2014 Mar;87(1035):20130676
pubmed: 24588669